AP125A - Pharmaceutical compositions for the regeneration of leukocytes and their use in the treatment of aquired immuno-deficiency syndrome - Google Patents
Pharmaceutical compositions for the regeneration of leukocytes and their use in the treatment of aquired immuno-deficiency syndrome Download PDFInfo
- Publication number
- AP125A AP125A APAP/P/1990/000157A AP8900157A AP125A AP 125 A AP125 A AP 125A AP 8900157 A AP8900157 A AP 8900157A AP 125 A AP125 A AP 125A
- Authority
- AP
- ARIPO
- Prior art keywords
- tetrahydroacridine
- pharmaceutical compositions
- group
- amino
- lymphocytes
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 15
- 230000008929 regeneration Effects 0.000 title claims description 5
- 238000011069 regeneration method Methods 0.000 title claims description 5
- 208000033065 inborn errors of immunity Diseases 0.000 title abstract 2
- 208000028529 primary immunodeficiency disease Diseases 0.000 title abstract 2
- 210000000265 leukocyte Anatomy 0.000 title description 2
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000002243 precursor Substances 0.000 claims abstract description 12
- 150000001875 compounds Chemical class 0.000 claims abstract description 11
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 239000003443 antiviral agent Substances 0.000 claims abstract description 9
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000002253 acid Substances 0.000 claims abstract description 6
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims abstract description 5
- 231100000252 nontoxic Toxicity 0.000 claims abstract description 5
- 230000003000 nontoxic effect Effects 0.000 claims abstract description 5
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical class O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims abstract description 4
- 239000003937 drug carrier Substances 0.000 claims abstract description 3
- 239000012458 free base Substances 0.000 claims abstract description 3
- 239000003981 vehicle Substances 0.000 claims abstract description 3
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims abstract 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims abstract 2
- 229940045145 uridine Drugs 0.000 claims abstract 2
- 210000004698 lymphocyte Anatomy 0.000 claims description 13
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 7
- 239000000787 lecithin Substances 0.000 claims description 7
- 235000010445 lecithin Nutrition 0.000 claims description 7
- 229940067606 lecithin Drugs 0.000 claims description 7
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- 125000002252 acyl group Chemical group 0.000 claims description 3
- 125000001931 aliphatic group Chemical group 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 150000004646 arylidenes Chemical group 0.000 claims description 2
- QPAARLKPLQNQBS-UHFFFAOYSA-N 1,2,3,4-tetrahydroacridin-1-amine Chemical compound C1=CC=C2C=C3C(N)CCCC3=NC2=C1 QPAARLKPLQNQBS-UHFFFAOYSA-N 0.000 claims 1
- FLTVDXBUZLYLDW-UHFFFAOYSA-N 9-benzylidene-2,3,4,9a-tetrahydroacridin-1-imine Chemical compound C(C1=CC=CC=C1)=C1C2=CC=CC=C2N=C2CCCC(C12)=N FLTVDXBUZLYLDW-UHFFFAOYSA-N 0.000 claims 1
- WBLGDOQKTYVVGF-UHFFFAOYSA-N 9-propan-2-ylidene-2,3,4,9a-tetrahydroacridin-1-imine Chemical compound C(C)(C)=C1C2=CC=CC=C2N=C2CCCC(C12)=N WBLGDOQKTYVVGF-UHFFFAOYSA-N 0.000 claims 1
- 150000001735 carboxylic acids Chemical class 0.000 claims 1
- 208000024891 symptom Diseases 0.000 abstract description 4
- 238000011084 recovery Methods 0.000 abstract description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- 230000001172 regenerating effect Effects 0.000 abstract 2
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 239000002547 new drug Substances 0.000 abstract 1
- 229940035893 uracil Drugs 0.000 abstract 1
- -1 alkyl radicals Chemical class 0.000 description 10
- LXHOFEUVCQUXRZ-RRKCRQDMSA-N 6-azathymidine Chemical compound O=C1NC(=O)C(C)=NN1[C@@H]1O[C@H](CO)[C@@H](O)C1 LXHOFEUVCQUXRZ-RRKCRQDMSA-N 0.000 description 7
- 241000862632 Soja Species 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- RXBYRTSOWREATF-UHFFFAOYSA-N 1,2,3,4-tetrahydroacridine Chemical compound C1=CC=C2C=C(CCCC3)C3=NC2=C1 RXBYRTSOWREATF-UHFFFAOYSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 description 1
- GOWMBYUZXIZENX-CAUSLRQDSA-N 1-[(2r,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-(hexadecylamino)pyrimidin-2-one Chemical compound O=C1N=C(NCCCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 GOWMBYUZXIZENX-CAUSLRQDSA-N 0.000 description 1
- ZEIYLROOZCYYKO-UHFFFAOYSA-N 1-benzylidene-2,3,4,9a-tetrahydroacridin-9-imine Chemical compound C(C1=CC=CC=C1)=C1CCCC2=NC3=CC=CC=C3C(C12)=N ZEIYLROOZCYYKO-UHFFFAOYSA-N 0.000 description 1
- FGBRUIVBHMUQPM-UHFFFAOYSA-N 1-methylidene-2,3,4,9a-tetrahydroacridin-9-imine Chemical compound C=C1CCCC2=NC3=CC=CC=C3C(C12)=N FGBRUIVBHMUQPM-UHFFFAOYSA-N 0.000 description 1
- RTHHTTRUEGUKEF-UHFFFAOYSA-N 1-propan-2-ylidene-2,3,4,9a-tetrahydroacridin-9-imine Chemical compound N=C1C2=CC=CC=C2N=C2CCCC(C12)=C(C)C RTHHTTRUEGUKEF-UHFFFAOYSA-N 0.000 description 1
- HZNQSWJZTWOTKM-UHFFFAOYSA-N 2,3,4-trimethoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C(OC)=C1OC HZNQSWJZTWOTKM-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- RWHOZGRAXYWRNX-VFUOTHLCSA-N alpha-D-glucose 1,6-bisphosphate Chemical compound O[C@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H](OP(O)(O)=O)[C@@H]1O RWHOZGRAXYWRNX-VFUOTHLCSA-N 0.000 description 1
- HXXFSFRBOHSIMQ-VFUOTHLCSA-N alpha-D-glucose 1-phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(O)=O)[C@H](O)[C@@H](O)[C@@H]1O HXXFSFRBOHSIMQ-VFUOTHLCSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000002647 anti-cholinesterasic effect Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229930183167 cerebroside Natural products 0.000 description 1
- RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 229940114119 gentisate Drugs 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229950010772 glucose-1-phosphate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 239000007887 hard shell capsule Substances 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012961 medicinal therapy Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000000842 neuromuscular blocking agent Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229960001685 tacrine Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-L thiosulfate(2-) Chemical compound [O-]S([S-])(=O)=O DHCDFWKWKRSZHF-UHFFFAOYSA-L 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000008979 vitamin B4 Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
- C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- C07D219/08—Nitrogen atoms
- C07D219/10—Nitrogen atoms attached in position 9
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
This invention relates to novel pharmaceutical compositions, to new products and to method for regenerating or improving the level of T lymphocytes in patients suffering from immuno-deficiency syndrome. The new pharmaceutical compositions according to this invention contain as active ingredient at least one compound selected from the group consisting of 9-amino 1,2,3,4-Tetrahydroacridine, in the free base form or as an acid addition salt, and its biological precursors, in admixture or conjunction with an inert non toxic pharmaceutically-acceptable carrier or vehicle. This invention also extends to a method for regenerating or improving the count of T4 lymphocytes in patients suffering from said symptoms alone or in addition with a therapy with an antiviral drug selected from the group consisting of derivatives of Thymidine, Uracil and Uridine. These new drugs may be given to children as well as to adults for an extended period of time with significant evidence of recovery.
Description
NEW PHARMACEUTICAL COMPOSITIONS AND NEW PHARMACEUTICAL PRODUCTS
ALLOWING THE REGENERATION OF LEUKOCYTES AND THEIR USE IN THE TREATMENT
IMMUNO-DEFICIENT SYNDROM
This invention relates to the field of medicinal therapy and more particularly to the field of immunological therapy.
It has more precisely as subject matter some products and some pharmaceutical compositions which allow to obtain alone or in combination with another active ingredient the treatment of acquired or non-acquired immuno deficitary syndroms.
Specifically it provides pharmaceutical compositions intended for the regeneration of lymphocytes T^ or the increase of the number of lymphocytes T^ in patients showing an immuno-deficitary syndrom which contain as active ingredient the 9-(or 5)amino
as a free base or in the form of a salt or a biological precursor thereof in admixture or conjunction with an inert non-toxic pharmaceutically-acceptable carrier or vehicle.
This invention precursors of formula also relates as new compounds to the biological 9-amino 1,2,3,4-Tetrahydroacridine having the
In which A and B are labile, functional groupings which are easily split in the body and namely in the digestive tract.
bad ORIGINAL
- 2 Among the labile groupings A and B, it may be cited the acyl residues of an organic aliphatic or aromatic, carboxylic acid, lower alkyl radicals or the alkoylidene or arylidene moiety of a Schiff’s Base deriving from a ketone of the formula or from an aldehyde of the formula
R1 - CHO wherein R1 is a lower alkyl radical, a monocyclic aryl radical which is unsubstituted or substituted by one, two or three substituents, a monocyclic heterocyclic radical and R2, is a hydrogen or a R^ radical
In the foregoing, the acid addition salt of 9-amino tetrahydro acridine or of the derivatives thereof are those obtained by adding a mineral or organic therapeutically-compatible acid such as a hydrochloride, a hydrobromide, a sulphate, a nitrate, a phosphate, a sulphite, a thiosulphate, an acetate, a butyrate, a caproate, a suberate, a succinate, a tartarate, a citrate, an ascorbate, a gluconate, a cetoglutarate, a glutamate, an aspartate, a benzoate, a gentisate, a salicylate, a trimethoxybenzoate, a vanillinate, an eugenate, a nicotinate, a naphtoate, a benzene sulfonate, a methane sulfonate, an isethionate, an ethane sulfonate, a p.toluene sulfonate, a camphosulfonate, a naphtalene sulfonate, a glucose 1-phosphate and a glucose 1,6-diphosphate.
The biological precursors of 9-amino 1,2,3,4-Tetrahydroacridine are namely the mono- and di-acyl amines such as for example :
- the compounds of formula
AP 0 0 0 1 2 5
BAD ORIGINAL
- 3 NHAC
N in which Ac is the acyl residue such as acetyl, propionyl, benzoyl,
- the compounds of formula
N
wherein Ac and Ac' the same or different are selected from the group consisting of alkanoyl radicals with 1 to 6 carbon atoms and mono- cyclic aroyl radicals which are unsubstituted or substituted with from 1 to 3 usual substituent
- the compounds of formula wherein R^ is a lower alkyl radical, a phenyl or a substitued phenyl
- the compounds of formula
wherein R^ and R2 the same or different are selected from the group consisting of a lower alkyl radical, a phenyl radical, and a monocyclic heterocyclic radical.
9-amino 1,2,3,4-Tetrahydroacridine is a known therapeutic agent already used under the Trade Name Tacrine for many years as an antidote of the curarizing agents and the cholines terasic agents. Its use has also been proposed in the treatment of Alzeimer's disease as anticholinesterasic agent and cerebral stimulant but its efficiency can not yet be judged lacking the necessary background. The mode of action of this active ingredient is still not determined with certainty due to the high number of pharmacological studies performed thereon.
Now it has been found that 9-amino 1,2,3,4-Tetrahydroacridine and the acid addition salts thereof as well as their biological precursors (pro-drugs) are- efficient drugs for allowing the regeneration of lymphocytes T^ and more particularly lymphocytes the number of which significantly and dangerously, decreases during and in the cases of immuno-deficitary syndrom.
It has been evidenced in patients the number of lymphocytes T^ of which was deeply decreased, that it was possible after few weeks of treatment to obtain a very marked increase of the levels of lymphocytes in the blood and that in patient where the count of lymphocytes has fallen to a level close of the disappearance, it was possible to get under the same conditions a recovery to subnormal levels of lymphocytes T^. At the same time the clinical cases stated a significant regression of the opportunistic infections symptoms and/or the disappearance of the seropositivity.
AP 0 0 0 1 2 5
BAD ORIGINAL β
- 5 9-amino 1,2,3,4-Tetrahdroacridine appears to act mainly as an inhibitor of the RNA polymerase of the viruses and more precisely of the HIV Viruses which are involved in the origin of AIDS.
The biological precursors of 9-amino tetrahydroacridine behalve in about the same manner and lead to the formation of 9-amino tetrahydroacridine in the stomach. It has been shown that in an artificial gastric juice, at pH 1, methylene 9-imino tetrahydroacridine, isopropylidene 9-imino tetrahydroacridine or benzylidene 9-imino tetrahydroacridine are split into the 9-amino derivative in about quantitative manner in less than 15 mn.
9-amino tetrahydroacridine and its biological precursors are also endowed with the ability to strenghten the action of antiviral drugs such as the thymidine, Uracile or uridine derivatives (AZT, DDI namely) and thus to allow a very marked decrease of the doses of antiviral drug to be efficient.
It is now known that the treatment of AIDS using Azathymidine (AZT) progressively losses its efficacy and let an only very limited chance of life to the patients affected with AIDS. The mixed treatment of AIDS with an antiviral drug and with 9-amino tetrahydroacridine or a salt thereof or one of its biological precursors have shown a significant presumption of life. It appears as very significative the clinical case of a patient treated for 15 months with AZT for which the number of lymphocytes
T. was about zero and after treatment with 9-amino 4
1,2,3,4-Tetrahydroacridine was still alive. It exists accordingly two possible therapeutic schemes :
- administration of 9-amino tetrahydroacridine alone
- or administration of 9-amino tetrahydroacridine in admixture or in support of a treatment with an antiviral drug.
In the case of antiviral drugs such as AZT or HPAZI, it has been shown a synergistic action which allows a decrease in the dosology of the antiviral drug of a factor of 10 while preserving the efficacy of the antiviral drug.
Λ
- 6 The pharmaceutical compositions according to this invention contain from 40 to 300 mg of 9-amino 1,2,3,4-tetrahydroacridine or an addition salt thereof or one of its biological precursors in admixture or conjunction with an inert non-toxic pharmaceutical ly-accep table diluent or carrier and preferably from 50 to 200 mg of active ingredient.
As preferred diluent it may be cited a lecithin such as soja lecithin, or a phospholipid such as a gangl ioside or a cerebroside, or a chemically-modified cellulose such as hydroxypropyl methylcellulose.
Among the pharmaceutical compositions according to this invention which contain as active ingredient either 9-amino tetrahydroacridine or a salt thereof or a biological precursor, it may be cited those which are suitable for the administration through the digestive route such as tablets, coated tablets, microgranules with protracted release, dragees, the soft gelatine capsules, the capsules, the hard shell capsules, the lozenges, the solutions or suspensions to be drunk, the jellies and the emulsions (O/W).
For the parenteral administration it will be preferably used a solution or suspension of active ingredient divided in ampuls, in «
multidoses flasks, or auto-in jectible syringes ; they are preferably utilized in the form of an acid addition salt.
For the rectal way they will be preferably be given in the form of rectal suppositories or capsules.
These pharmaceutical compositions are manufactured in accordance with the usual methods of pharmacotechnology. The following examples are intended to illustrate the invention without limiting it in any manner.
AP 0 0 0 1 2 5
BAD ORIGINAL
- 7 EXAMPLE I
Tablets with 100 g of 9-amino 1,2,3,4-tetrahydroacridine . 9-amino 1,2,3,4-tetrahydroacridine as the hydrated hydrochloride ...................... 117 g . Lactose .......’.............................. 220 g . microcristalline cellulose .................. 15 g . Calcium Carbonate ........................... 20 g . Calcium Phosphate (PO4)2 Ca3 ................ 35 9 . Copolymer of ethylene oxyde and propylene oxyde sold under the Trade Name PLURONIC F18 . 13 g . Magnesium stearate ........................... 15 g for 1000 tablets finished at the mean weight of .43 g
EXAMPLE II
Clinical Trial with 9-amino 1,2,3,4-tetrahydroacridine in patients suffering from immuno-deficitary syndrom
| PATIENTS | DOSIS | CONCENTRATION LYMPHOCYTES T4 BEFORE per mm3 | CONCENTRATION LYMPHOCYTES T4 AFTER per mm3 | I SYMPTOMS OF CLINICAL IMPROVEMENT |
| 1 | 100 mg/day | 0 | 600 | Becomes sero- |
| 5 months | negative | |||
| 2 | 100 mg/day | 80 | 250 | Decrease of |
| 3 months | the infectious symptoms | |||
| 3 | 100 mg/day | 80 | 210 | No marked |
| 2 months | symptom of infection | |||
| 4 | 100 mg/day 2 months | 100 | 270 | -d°- |
| 5 | 200 mg/day | 80 | 200 | Regression of the |
| 2 months | opportunist infections | |||
| Normal | level in T4 is | 600-800 per mm3 |
bad origin*1·
EXAMPLE III
Determination of the inhibitory action of 9-amino 1,2,3,4-Tetrahydroacridine (THA) against RNA polymerase of HIV Viruses.
In vitro THA inhibits RNA polymerase of HIV Viruses with a close window of efficiency at 0,1 jumol/1--» 0% inhibition pmol/1--> 100 % inhibition
EXAMPLE IV
Methodology of the clinical trials
a) in the adults . 1st week : 50 mg/day + 1200 mg soja lecithin . 2nd week : 100 mg/day + 1200 mg soja lecithin . 3rd week : 150 mg/day if necessary + soja lecithin . 4th week : 200 mg/day if necessary + soja lecithin
b) in the children
The treatement is started at 10 up to 25 mg/day.
An adult patient formerly treated with AZT after what, his blood level in was about zero, has been given 9-amino 1,2,3,4Tetrahydroacridine up to 100 mg/day. After 5 months of this treatment, the lymphocytes have been increased and the patient was still alive, whilst under treatment with AZT alone, the presumption of his survival was minimal.
Claims (10)
1·- A process for producing pharmaceutical compositions intended to allow the regeneration of lymphocytes t^ or the increase of their number in p>atients suffering from an immunodeficitary syndrom which comprises mixing a compound selected from the group consisting of 9 (or 5) amino
1,2,3,4-tetrahydroacridine of the formula as the free base or as an acid addition salt thereof and one of its biological precursors with an inert non-toxic pharmaceutically-acceptable carrier or vehicle
2e- A pharmaceutical composition according to claim 1 wherein the content in active ingredient ranges from lOto 300 mg per unit dosage.
3·- A pharmaceutical composition according to claim 1’ which further contains an antiviral drug selected from the group consisting of derivatives of Thymidine, Uracile and Uridine.
4°- As new compounds the biological precursors of 9-amino
1,2,3,4-Tetrahydroacridine having the formula wherein A and B are labile fonctional groupings selected from the group consisting of acyl residues from aliphatic or *
- 10 aromatic organic carboxylic acids, lower alkyl radicals, an alkoylidene group and a arylidene groupe
5e- A compound according to claim 4° which is 9-methylene imino
1.2.3.4- Tetrahydroacrdine.
<
6·- A compound according to claim 4® which is 9-isopropylidene imino 1,2,3,4-Tetrahydroacridine.
7e- A compound according to claim 4° which is 9-benzylidene imino
1.2.3.4- Tetrahydroacridine.
8’- A pharmaceutical composition according to claim 1° in which the inert carrier is one of those suitable for administration through the parenteral, oral, rectal, percutaneous or permucous routes of administration.
9*- The pharmaceutical compositions according to claim 8° wherein the amount of active ingredient ranges from 10 to 200 mg per unit dosage.
10e- The pharmaceutical composition according to any of claims 8 to 9° in which the inert non-toxic carrier is lecithin.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR888816749A FR2640508B1 (en) | 1988-12-19 | 1988-12-19 | NOVEL COMPOSITIONS AND NEW PHARMACEUTICAL PRODUCTS ENSURING THE REGENERATION OF LEUKOCYTES AND THEIR USE FOR THE TREATMENT OF IMMUNE DEFICIT SYNDROME |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AP8900157A0 AP8900157A0 (en) | 1990-01-31 |
| AP125A true AP125A (en) | 1991-03-19 |
Family
ID=9373109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| APAP/P/1990/000157A AP125A (en) | 1988-12-19 | 1989-12-18 | Pharmaceutical compositions for the regeneration of leukocytes and their use in the treatment of aquired immuno-deficiency syndrome |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP0375471B1 (en) |
| JP (1) | JPH02258722A (en) |
| KR (1) | KR900009075A (en) |
| AP (1) | AP125A (en) |
| AT (1) | ATE136463T1 (en) |
| AU (2) | AU4686189A (en) |
| CA (1) | CA2005925C (en) |
| DE (1) | DE68926222D1 (en) |
| DK (1) | DK646489A (en) |
| FR (1) | FR2640508B1 (en) |
| HU (1) | HU213510B (en) |
| IL (1) | IL92759A (en) |
| MA (1) | MA21964A1 (en) |
| MY (1) | MY106032A (en) |
| NZ (1) | NZ231854A (en) |
| OA (1) | OA09250A (en) |
| PT (1) | PT92620B (en) |
| TN (1) | TNSN89135A1 (en) |
| ZA (1) | ZA899733B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5155226A (en) * | 1991-02-19 | 1992-10-13 | Hoechst-Roussel Pharmaceuticals Incorporated | Method for the preparation of 9-amino-1,2,3,4-tetrahydroacridine |
| EP0509401A1 (en) * | 1991-04-19 | 1992-10-21 | Hoechst-Roussel Pharmaceuticals Incorporated | Use of 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds for the treatment of aids |
| RU2036198C1 (en) * | 1993-04-01 | 1995-05-27 | Товарищество с ограниченной ответственностью "Полисан" | N-METHYL- N- (α-D- GLUCOPYRANOSYL) -AMMONIUM -2-(ACRIDONE -9-ONE -10-YL) -ACETATE (CYCLOFERON) SHOWING INTERFEROGENIC, ANTIVIRAL AMONG THEM ANTI-HIV, ANTIPARASITIC, ANTIPROMOTER AND RADIOPROTECTIVE ACTIVITIES |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0319429A2 (en) * | 1987-12-03 | 1989-06-07 | Mitsubishi Kasei Corporation | 9-Acylamino-tetrahydroacridine derivatives and memory enhancing agent containing said derivative as active ingredient |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4916122A (en) * | 1987-01-28 | 1990-04-10 | University Of Georgia Research Foundation, Inc. | 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition |
| JPH02500364A (en) * | 1986-11-21 | 1990-02-08 | マツクス‐プランク‐ゲゼルシヤフト ツール フエルデルング デル ヴイツセンシヤフテン エー フアウ | Methods for treating viral infections in humans and compositions therefor |
| IL86009A (en) * | 1987-04-10 | 1991-09-16 | Us Health | Liposome-encapsulated phosphorylated nucleosides for treatment of retroviral diseases |
| US5013741A (en) * | 1987-09-08 | 1991-05-07 | Hoechst-Roussel Pharmaceuticals Incorporated | N-[substituted alkylidene]-1,2,3,4-tetrahydro-9-acridinamines useful for enhancing the cholinergic function in a mammal |
| CH678275A5 (en) * | 1989-05-25 | 1991-08-30 | Debiopharm Sa | |
| US4999358A (en) * | 1989-06-26 | 1991-03-12 | Hoechst-Roussel Pharmaceuticals Inc. | (1,2,3,4-tetrahydro-9-acridinimino)cyclohexane carboxylic acid and related compounds |
| US4999430A (en) * | 1989-07-31 | 1991-03-12 | Warner-Lambert Company | Derivatives of 1,2,3,4-tetrahydro-9-acrisinamine |
-
1988
- 1988-12-19 FR FR888816749A patent/FR2640508B1/en not_active Expired - Fee Related
-
1989
- 1989-09-29 DE DE68926222T patent/DE68926222D1/en not_active Expired - Lifetime
- 1989-09-29 EP EP89402687A patent/EP0375471B1/en not_active Expired - Lifetime
- 1989-09-29 AT AT89402687T patent/ATE136463T1/en not_active IP Right Cessation
- 1989-12-18 IL IL9275989A patent/IL92759A/en not_active IP Right Cessation
- 1989-12-18 AP APAP/P/1990/000157A patent/AP125A/en active
- 1989-12-18 MA MA21958A patent/MA21964A1/en unknown
- 1989-12-18 MY MYPI89001798A patent/MY106032A/en unknown
- 1989-12-19 NZ NZ231854A patent/NZ231854A/en unknown
- 1989-12-19 OA OA59701A patent/OA09250A/en unknown
- 1989-12-19 PT PT92620A patent/PT92620B/en not_active IP Right Cessation
- 1989-12-19 ZA ZA899733A patent/ZA899733B/en unknown
- 1989-12-19 KR KR1019890019125A patent/KR900009075A/en not_active Ceased
- 1989-12-19 CA CA002005925A patent/CA2005925C/en not_active Expired - Fee Related
- 1989-12-19 HU HU896683A patent/HU213510B/en not_active IP Right Cessation
- 1989-12-19 JP JP1329377A patent/JPH02258722A/en active Pending
- 1989-12-19 TN TNTNSN89135A patent/TNSN89135A1/en unknown
- 1989-12-19 AU AU46861/89A patent/AU4686189A/en not_active Abandoned
- 1989-12-19 DK DK646489A patent/DK646489A/en not_active Application Discontinuation
-
1993
- 1993-05-25 AU AU39806/93A patent/AU666725B2/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0319429A2 (en) * | 1987-12-03 | 1989-06-07 | Mitsubishi Kasei Corporation | 9-Acylamino-tetrahydroacridine derivatives and memory enhancing agent containing said derivative as active ingredient |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2005925C (en) | 2002-03-26 |
| PT92620B (en) | 1995-09-12 |
| IL92759A0 (en) | 1990-09-17 |
| TNSN89135A1 (en) | 1991-02-04 |
| EP0375471A2 (en) | 1990-06-27 |
| DK646489A (en) | 1990-06-20 |
| FR2640508B1 (en) | 1994-07-01 |
| OA09250A (en) | 1992-06-30 |
| AU4686189A (en) | 1990-06-21 |
| CA2005925A1 (en) | 1990-06-19 |
| PT92620A (en) | 1990-06-29 |
| EP0375471A3 (en) | 1992-07-08 |
| HU896683D0 (en) | 1990-02-28 |
| FR2640508A1 (en) | 1990-06-22 |
| AP8900157A0 (en) | 1990-01-31 |
| EP0375471B1 (en) | 1996-04-10 |
| DK646489D0 (en) | 1989-12-19 |
| JPH02258722A (en) | 1990-10-19 |
| DE68926222D1 (en) | 1996-05-15 |
| HU213510B (en) | 1997-07-28 |
| ZA899733B (en) | 1991-04-24 |
| MA21964A1 (en) | 1991-07-01 |
| AU3980693A (en) | 1993-08-19 |
| KR900009075A (en) | 1990-07-02 |
| IL92759A (en) | 1994-06-24 |
| NZ231854A (en) | 1993-01-27 |
| MY106032A (en) | 1995-02-28 |
| ATE136463T1 (en) | 1996-04-15 |
| AU666725B2 (en) | 1996-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2179521C (en) | 2,4-disulphophenyl butylnitrone, its salts and their use as pharmaceuti cal spintraps | |
| CA1238277A (en) | Antiviral nucleosides | |
| JP2540576B2 (en) | Antiretrovirus and hepatitis B agent | |
| US5026716A (en) | Method of treatment of anxiety and anxio-depressive disorders | |
| AP125A (en) | Pharmaceutical compositions for the regeneration of leukocytes and their use in the treatment of aquired immuno-deficiency syndrome | |
| JPH02243666A (en) | Method of therapy and prophylaxis of pneumocystis carinii pneumonia,and compound and prescribed drug used in these methods | |
| US20040171636A1 (en) | Treatment of viral infections | |
| EP1210116B1 (en) | Pharmaceutical combination for the treatment of viral infections containing a calcium channel blocker and a quinoline | |
| US3979511A (en) | Inhibitors of reverse transcriptase enzymes | |
| US5541212A (en) | Use of cimetidine for the control of retrovirus infections | |
| KR930000049B1 (en) | Treatment of Chemical Dependence Using Cetralline | |
| JPS61257925A (en) | Antiviral nucleoside | |
| US5886000A (en) | Anti-HIV agent | |
| US5278167A (en) | 6-pyridyl substituted pyrimidine derivatives | |
| EP0555302A1 (en) | Method of treating demyelinating disease | |
| EP0697215A1 (en) | Digestive symptom ameliorant | |
| AU2025205507A1 (en) | A protease inhibitor and the pharmaceutical salt thereof | |
| CA1340519C (en) | Antiviral nucleosides | |
| JPWO1995020388A1 (en) | anti-HIV drugs | |
| IL85096A (en) | Use of 3'-azido-3'- deoxythymidine in the treatment of prophylaxis of human retrovirus infection | |
| WO1989002741A1 (en) | Inhibitors of hiv-reverse transcriptase to treat aids | |
| WO1989002741A2 (en) | Inhibitors of hiv-reverse transcriptase to treat aids |